What happens to your body when you take Mounjaro long term?
Mounjaro (tirzepatide) is one of the most talked-about medications in weight management right now, and with good reason. Recent research shows that participants on the highest dose of tirzepatide achieved an average weight reduction of 22.5% over 72 weeks. For context, that is roughly the kind of result previously only seen with bariatric surgery.
But effectiveness alone does not tell the whole story. Mounjaro is a powerful medication that works by targeting two hormonal pathways simultaneously, GLP-1 and GIP receptors, to reduce appetite, slow gastric emptying and improve how the body handles glucose and fat. These are not minor biological changes. They require clinical oversight, regular monitoring, and a long-term treatment plan.
This article looks at what the published evidence actually says about taking tirzepatide long term, what the risks are, and why having a doctor actively involved in your care is essential rather than optional.
What happens when you stop taking Mounjaro
One of the most important things to understand about tirzepatide is that it is not a course of treatment you complete and walk away from. The evidence consistently shows that stopping the medication leads to significant weight regain.
A recent study was carried out to test this. After 36 weeks of open-label treatment with tirzepatide, participants were randomised to either continue or switch to placebo for a further 52 weeks. Those who continued the medication maintained and even increased their weight loss. Those who stopped regained weight substantially.
A post hoc analysis of this trial broke this down further. Among participants who discontinued tirzepatide, 82.5% regained at least a quarter of the weight they had initially lost. Crucially, the degree of weight regain was directly linked to the reversal of cardiometabolic benefits. Those who regained the most weight saw their improvements in blood pressure, cholesterol, blood glucose and insulin resistance return to baseline levels.
The authors of the study were unambiguous in their conclusions. Long-term treatment with obesity management medications is likely necessary to sustain both weight reduction and the associated health benefits. This mirrors how we treat other chronic conditions. No one expects blood pressure medication to keep working after you stop taking it, and the same logic applies here.
How Mounjaro affects muscle mass and body composition
Weight loss is not just about the number on the scale. What you lose matters. And this is one of the areas where medical supervision becomes particularly important.
A comprehensive review published in Diabetes, Obesity and Metabolism in 2024 examined changes in lean body mass across GLP-1 based therapies. In the trial, lean mass accounted for approximately 25% of total weight lost with tirzepatide at the highest dose. In comparison, semaglutide trials have shown lean mass accounting for up to 40% of total weight lost.
This does not mean that tirzepatide causes muscle wasting. A 2025 MRI substudy found that tirzepatide actually reduced fat infiltration within muscle tissue, which is a marker of improved muscle quality. The reductions in muscle volume were broadly in line with what would be expected for the amount of weight lost.
However, without the right support, lean mass loss can become clinically significant. A case series published in 2025 demonstrated that patients who combined GLP-1 therapy with structured resistance training (three to five sessions per week) and adequate protein intake (0.7 to 1.7g per kilogram of body weight daily) were able to preserve or even increase their lean tissue while losing substantial amounts of fat.
The takeaway is clear. Body composition monitoring, dietary guidance and an exercise plan are not extras. They are essential components of safe and effective treatment.
What are the gastrointestinal and metabolic risks of long-term use
The most commonly reported side effects of tirzepatide are gastrointestinal. Nausea, vomiting, diarrhoea and constipation are well documented across trial programmes, and they tend to be most pronounced during dose escalation. For most patients, these symptoms improve as the body adjusts to each new dose level.
More concerning are the rarer but more serious risks that emerge with extended use. A systematic review and meta-analysis of nine randomised controlled trials found that tirzepatide was associated with a statistically significant increased risk of gallbladder or biliary disease when compared with placebo or basal insulin. Rapid weight loss is a well-established risk factor for gallstone formation, and clinicians need to be alert to symptoms such as right-sided abdominal pain, particularly in the first year of treatment.
Pancreatitis has been flagged as a theoretical concern for all incretin-based therapies, though current meta-analyses have not found a statistically significant increased risk with tirzepatide specifically. The same review of nine RCTs reported no significant association between tirzepatide and pancreatitis. Nonetheless, the prescribing information advises against use in patients with a history of pancreatitis, and clinicians should screen for risk factors before starting treatment.
A 2025 analysis also revealed that dosing errors were the single most frequently reported problem with tirzepatide, increasing eightfold between 2022 and 2024. This is a practical, avoidable issue that underscores the value of having a clinical team guide patients through the titration process.
Can Mounjaro cause nutritional deficiencies
When appetite is significantly suppressed, caloric intake drops. This is the mechanism that drives weight loss, but it also means that patients may struggle to meet their nutritional needs without conscious effort and clinical guidance.
Reduced food intake can lead to inadequate levels of protein, iron, vitamin B12, folate, vitamin D and calcium, among others. These deficiencies can develop gradually and may not produce obvious symptoms until they are well established. Low vitamin D, for example, impairs both muscle function and bone health. Iron deficiency leads to fatigue, reduced exercise tolerance and impaired immunity. Insufficient protein intake accelerates the loss of lean mass discussed above.
Regular blood monitoring allows a clinical team to identify and correct these issues before they become problematic. This is particularly important for patients on higher doses of tirzepatide, where appetite suppression is most pronounced, and for those on long-term treatment where cumulative deficits can develop.
Why a doctor needs to be involved in your Mounjaro treatment
The rise of online-only prescribing services has made GLP-1 medications more accessible, but accessibility without adequate clinical oversight carries real risks. A thorough, doctor-led weight loss programme should include several key elements.
Before starting treatment, patients need a full clinical assessment including screening for contraindications. Tirzepatide carries a boxed warning regarding the risk of medullary thyroid carcinoma based on animal studies, and it should not be prescribed to patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2. A history of pancreatitis, gallbladder disease, or severe gastrointestinal conditions also requires careful evaluation.
During treatment, ongoing monitoring should include regular blood tests to track metabolic markers, kidney and liver function, thyroid health, and nutritional status. Body composition assessments help ensure that weight loss is coming predominantly from fat rather than lean tissue. Dose titration should be guided by clinical response and tolerability, not a fixed schedule.
Equally important is the integration of lifestyle support. The evidence from both clinical trials and real-world studies is consistent. Patients who combine medication with structured exercise, adequate protein intake and behavioural support achieve better and more sustainable outcomes than those relying on the drug alone.
How The Wellness can help
At The Wellness, we offer a medically supervised weight loss programme that provides GLP-1 prescriptions, including tirzepatide, under the care of a full healthcare team. Every patient receives a comprehensive clinical assessment before starting treatment, regular blood monitoring throughout, body composition tracking, personalised dietary and exercise guidance, and structured clinical reviews at every stage.
Our approach is built on the principle that effective weight management requires more than a prescription. It requires a team. If you are considering Mounjaro, or if you are currently taking it without structured medical support, we would welcome the opportunity to discuss how our programme can help you achieve safer, more sustainable results.
To find out more or book a consultation, visit thewellnesslondon.com.
